- Home
- CGC vs OBIO Comparison
CGC vs OBIO Comparison
Compare CGC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- OBIO
- Stock Information
- Founded
- CGC 2009
- OBIO 2017
- Country
- CGC Canada
- OBIO United States
- Employees
- CGC N/A
- OBIO N/A
- Industry
- CGC Pharmaceuticals and Biotechnology
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- CGC Health Care
- OBIO Health Care
- Exchange
- CGC Nasdaq
- OBIO Nasdaq
- Market Cap
- CGC 174.9M
- OBIO 151.3M
- IPO Year
- CGC N/A
- OBIO N/A
- Fundamental
- Price
- CGC $1.19
- OBIO $2.85
- Analyst Decision
- CGC Sell
- OBIO Strong Buy
- Analyst Count
- CGC 2
- OBIO 5
- Target Price
- CGC $2.00
- OBIO $15.00
- AVG Volume (30 Days)
- CGC 5.8M
- OBIO 69.1K
- Earning Date
- CGC 05-29-2025
- OBIO 05-12-2025
- Dividend Yield
- CGC N/A
- OBIO N/A
- EPS Growth
- CGC N/A
- OBIO N/A
- EPS
- CGC N/A
- OBIO N/A
- Revenue
- CGC $192,343,833.00
- OBIO $2,638,000.00
- Revenue This Year
- CGC N/A
- OBIO $27.37
- Revenue Next Year
- CGC $2.50
- OBIO $42.68
- P/E Ratio
- CGC N/A
- OBIO N/A
- Revenue Growth
- CGC N/A
- OBIO N/A
- 52 Week Low
- CGC $0.77
- OBIO $2.49
- 52 Week High
- CGC $14.92
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- CGC 55.54
- OBIO 36.86
- Support Level
- CGC $0.77
- OBIO $2.75
- Resistance Level
- CGC $0.98
- OBIO $3.26
- Average True Range (ATR)
- CGC 0.13
- OBIO 0.48
- MACD
- CGC 0.05
- OBIO -0.01
- Stochastic Oscillator
- CGC 79.25
- OBIO 16.82
About CGC Canopy Growth Corporation
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.